Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: advertising (52), promotion (54), selling (39)

Ipilimumab Ver 1

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB Regimen Skin – Ipilimumab Indication Ipilimumab is recommended, within its marketing authorisation, as an option for treating
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinIpilimumabVer1.pdf

Pertuzumab/Trastuzumab SC

Description: Chemotherapy Protocol BREAST CANCER Regimen Pertuzumab / Trastuzumab SC • Breast Cancer – Trastuzumab / Pertuzumab SC Indication • Treat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/PertuzumabTrastuzumab-SC.pdf

Engaging for increased research participation - full report

Description: Engaging for increased research participation Public and healthcare professionals' perceptions For further information contact: Chris Stock Head of R&D communications
Url: /Media/Southampton-Clinical-Research/Marketresearch/Engaging-for-increased-research-participation-full-report-v2.pdf

BEACON protocol v8.0 07Mar2023 signed

Description: A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

Remuneration and Appointment Committee ToR Feb 2023

Description: Remuneration and Appointment Committee Terms of Reference Date Issued: 28 February 2023 Review Date: February 2024 Document Type: Committee Terms of
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Remuneration-and-Appointment-Committee-ToR-Feb-2023.pdf

Remuneration and Appointment Committee ToR May 2022

Description: Remuneration and Appointment Committee Terms of Reference Date Issued: 26 May 2022 Review Date: November 2022 Document Type: Committee Terms of
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Remuneration-and-Appointment-Committee-ToR-May-2022.pdf

Atezolizumab(1680-28days)

Description: Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab (1680mg-28 days) Regimen • Urothelial– Atezolizumab (1680mg-28 days) Indication • This prot
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab1680-28days.pdf

Nivolumab 480mg (renal)

Description: Chemotherapy Protocol RENAL CELL CANCER Nivolumab (480mg-28 days) Regimen • Renal Cell – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-480mg.pdf

Nivolumab 240mg (renal)

Description: Chemotherapy Protocol RENAL CELL CANCER Nivolumab (240mg-14 days) Regimen • Renal Cell – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-240mg.pdf

Nivolumab 480mg skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab (480mg-28 days) Regimen • Skin – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within its marketing
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-480mg.pdf

41 to 50 of 70

Previous … 3 4 5 6 7 Next